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One of the hallmarks of human cancers is the intrinsic or acquired resistance to apoptosis. Evasion of apoptosis can be part of
a cellular stress response to ensure the cell’s survival upon exposure to stressful stimuli. Apoptosis resistance may contribute to
carcinogenesis, tumor progression, and also treatment resistance, since most current anticancer therapies including chemotherapy
as well as radio- and immunotherapies primarily act by activating cell death pathways including apoptosis in cancer cells. Hence,
a better understanding of the molecular mechanisms regarding how cellular stress stimuli trigger antiapoptotic mechanisms and
howthiscontributestotumorresistancetoapoptoticcelldeathisexpectedtoprovidethebasisforarationalapproachtoovercome
apoptosis resistance mechanisms in cancers.
1.Introduction
Tissue homeostasis is characterized by the balance between
proliferation and cell growth on one side and cell death
on the other side [1]. In response to stressful stimuli, cells
usually mount a cellular stress response to ensure survival
[2]. Under physiological conditions, such a stress response
limits tissue damage. However, in cancer cells activation
of pathways that favor cell survival instead of cell death
under stressful conditions may contribute to tumorigenesis.
In addition, this adaptive stress response promotes the
development of acquired resistance, since current treatment
approaches such as chemotherapy and irradiation trigger
cellular stress pathways, and thus, initiate the activation
of survival cascades and anti-apoptotic mechanisms [3].
Apoptosis or programmed cell death is the cell’s intrinsic
death program that regulates various physiological as well
as pathological processes and that is evolutionary highly
conserved [1]. Hence, further insights into the molecular
mechanisms of how cellular stress signals trigger anti-
apoptotic mechanisms and how this contributes to tumor
resistance to apoptotic cell death are expected to provide the




There are two major apoptosis signaling pathways, that is,
thedeathreceptor(extrinsic)pathwayandthemitochondrial
(intrinsic) pathway [4]. Under most circumstances, acti-
vation of either pathway eventually leads to proteolytic
cleavage and thus activation of caspases, a family of cysteine
proteases that act as common death eﬀector molecules
[5]. Accordingly, caspases are responsible for many of the
biochemical and morphological hallmarks of apoptotic cell
death by cleaving a range of substrates in the cytoplasm
or nucleus [5]. Ligation of death receptors of the tumor
necrosis factor (TNF) receptor superfamily such as CD95
(APO-1/Fas) or TRAIL receptors by their corresponding
natural ligands, that is, CD95 ligand or TRAIL, results in the
recruitment of caspase-8 into a multimeric complex at the
plasma membrane, the death-inducing signaling complex
(DISC) [6, 7]. This in turn leads to caspase-8 activation,
which can then directly cleave downstream eﬀector cas-
pases such as caspase-3 [7]. Alternatively, caspase-8 can
promote outer mitochondrial membrane permeabilization
bycleavingBid,aBH3-onlyproteinthattranslocatestomito-
chondria upon cleavage and causes cytochrome c release
[8]. The mitochondrial pathway is initiated by the release2 International Journal of Cell Biology
of apoptogenic factors such as cytochrome c, apoptosis-
inducing factor (AIF) second mitochondria-derived acti-
vator of caspase (Smac)/direct IAP Binding protein with
Low pI (DIABLO) or Omi/high temperature requirement
protein A (HtrA2) from the mitochondrial intermembrane
space into the cytosol [9]. The release of cytochrome c
into the cytosol triggers activation of caspase-3 via the
formation of a large cytosolic complex, which is called
the apoptosome and consists of cytochrome c, Apaf-1,
and caspase-9 [9]. Smac/DIABLO or Omi/HtrA2 promotes
caspase activation by binding to Inhibitor of Apoptosis
(IAP) proteins and thereby disrupts the interaction of
IAPs with caspase-3 or -9 [9, 10]. Accidental stimulation
of the apoptotic machinery can have detrimental eﬀects
on cell survival. Therefore, cancer cells react to cellular
stress signals by mounting an anti-apoptotic response,
which enables cancer cells to evade apoptotic cell death
and ensures cell survival [11]. A wide range of stress
signals has been identiﬁed, which may evoke a cell survival
program in case of sublethal damage, while cell death
is usually initiated if the damage is too severe, that is,
starvation, hypoxia, DNA damaging drugs, irradiation, ER
stress, and reactive oxygen species just to name a few
[2].
The molecular mechanisms that initiate cell death upon
cellular stress stimuli have often not exactly been identiﬁed
and likely depend on the individual stimulus. For example,
following exposure to genotoxic substances, damage to
DNA or to other critical molecules is considered to be
a common initial event which is then transmitted by the
cellular stress response to the activation of cellular eﬀector
systemssuchastheapoptoticmachinery[12].Variousstress-
inducible molecules, for example, JNK, MAPK/ERK, NF-
κB, or ceramide have been implicated in propagating the
apoptotic signal [13–15].
Besides caspase-dependent and caspase-independent
apoptosis, additional non-apoptotic modes of cell death
also exist and have gained increasing attention over the last
years, including necrosis, autophagy, mitotic catastrophe,
and lysosomal cell death [16, 17]. While resistance to these
cell death modalities can also contribute to evasion of
cell death under stress conditions, the discussion of these
alternative modes of cell death is beyond the scope of this
review.
3.Evasionof Apoptosis inResponse to
CellularStressinCancers
A characteristic feature of human cancers is the evasion of
apoptosis in response to stress stimuli, which contributes
to both tumorigenesis and treatment resistance [18]. In
principle, cell death pathways can be blocked at diﬀerent
levels of the signaling cascade by upregulation of anti-
apoptotic proteins and/or by downregulation or dysfunction
of proapoptotic molecules. Examples of altered apoptosis
signaling pathways that contribute to stress resistance in
human cancers will be discussed in the following paragraphs
(Figure 1).
3.1. Evasion of the Death Receptor Pathway. Death receptors
are part of the tumor necrosis factor (TNF) receptor gene
superfamily, which comprises more than 20 proteins, for
example, CD95 (APO − 1/Fas), TRAIL receptors, and TNF
r e c e p t o r1( T N F R I )[ 7, 19]. Death receptors exert many
diﬀerent biological functions, including the regulation of cell
death and survival, diﬀerentiation, and immune regulation
[7, 19]. Members of the TNF receptor family share a charac-
teristiccytoplasmicdomaincalledthe“deathdomain,”which
is pivotal for transducing the death signal from the cell’s
surface to intracellular signaling pathways [7, 19].
Signaling via death receptor can be impaired in human
cancers via downregulation of receptor surface expression
as part of an adaptive stress response. For example, in
chemotherapy-resistant leukemia or neuroblastoma cells,
downregulation of CD95 expression was identiﬁed as a
mechanism of acquired drug resistance [20, 21]. For the
apoptosis-inducing TRAIL receptors TRAIL-R1 and TRAIL-
R2, abnormal transport from intracellular stores such as
the endoplasmatic reticulum to the cell surface rendered
colon carcinoma cells resistant to TRAIL-induced cell death
[22]. Further, membrane expression of death receptors
can be reduced by epigenetic changes such as CpG-island
hypermethylation of gene promoters in response to stress
signals [23, 24].
Abnormal expression of decoy receptors presents an
alternative mechanism of resistance to TRAIL- or CD95-
induced apoptosis. To this end, the decoy receptor 3 (DcR3),
which counteracts CD95-mediated apoptosis by competi-
tively binding CD95 ligand, was shown to be overexpressed
in lung carcinoma or colon carcinoma and in glioblastoma
[25, 26] and TRAIL-R3; a decoy receptor for TRAIL was
reported to be expressed at high levels in gastric carcinoma
[27].
In addition, anti-apoptotic proteins with a death eﬀector
domain (DED) such as cellular FLICE-Inhibitory Protein
(cFLIP) and phosphoprotein enriched in diabetes/ phos-
phoproteinenrichedinastrocytes-15kDa(PED/PEA-15)can
be aberrantly expressed upon cellular stress [28, 29]. For
example, high oxygen tension (hyperoxia) has been reported
to lead to upregulation of cFLIP, which inhibited apoptosis
during hyperoxia by suppressing both extrinsic and intrinsic
apoptotic pathways, the latter via inhibition of Bax [30].
Because of their sequence homology to caspase-8, both
cFLIP and PED can be recruited into the death-inducing
signaling complex (DISC) upon receptor ligation instead of
procaspase-8, thereby preventing caspase-8 activation [28,
29].
Moreover, the expression of caspase-8 or its function is
impaired by genetic or epigenetic mechanisms in various
cancers. For example, caspase-8 mutations were identiﬁed
in some tumors, that is, in colorectal and head and neck
carcinomas, although the overall frequency is low [31, 32].
In addition, homo- or heterozygous genomic deletions
were detected in neuroblastoma [33]. Alternative splicing of
intron 8 of the caspase-8 gene resulting in the generation
of caspase-8L, a catalytically inactive splice variant presents
anothermechanismofcaspase-8inactivation[34,35].Epige-

























Figure 1: Interplay of cellular stress signals with apoptosis pathways. Signaling via the death receptor pathway can be inhibited by
downregulation or epigenetic silencing of death receptors (DRs) or upregulation of cFLIP by hyperoxia. In the mitochondrial pathway,
Bcl-2 favors a prooxidant milieu that promotes survival, while the reduced form of cytochrome c is inhibited in its activity to trigger caspase
activationviatheapoptosome.Atthepostmitochondriallevel,translationofXIAPandcIAP1issustainedviaanIRES-dependentmechanism
even under cellular stress conditions. See text for more details.
sequences of the caspase-8 gene occurs in various tumors,
for example, neuroblastoma, malignant brain tumors, Ewing
tumor, retinoblastoma, rhabdomyosarcoma, or small lung
cell carcinoma [33, 36–39]. Furthermore, phosphoryla-
tion of caspase-8 on tyrosine 308 by, for example, Src
has been shown to interfere with its proapoptotic activity
[40].
3.2. Evasion of the Mitochondrial Pathway
3.2.1. Bcl-2 Family Proteins. The Bcl-2 family of proteins
consists of both anti-apoptotic proteins, for example, Bcl-2,
Bcl-XL,a n dM c l - 1 ,a sw e l la sp r o a p o p t o t i cm o l e c u l e ss u c h
as Bax, Bak, and BH3 domain only molecules [8]. There are
currently two models to explain the activation of Bax and
Bak by BH3-only proteins. The direct activation model holds
that BH3-only proteins, which act as direct activators such
as Bim and the cleaved form of Bid (tBid), bind directly
to Bax and Bak to trigger their activation, while BH3-only
proteins that act as sensitizers, for example, Bad, bind to
the prosurvival Bcl-2 proteins [41]. According to the indirect
activation model, BH3-only proteins activate Bax and Bak in
an indirect fashion by engaging the multiple anti-apoptotic
Bcl-2 proteins that inhibit Bax and Bak, thereby releasing
their inhibition on Bax and Bak [42, 43]. Regardless of the
exact mode of Bax and Bak activation, the ratio of anti-
apoptotic versus proapoptotic Bcl-2 proteins rather than the
expression levels of one particular molecule of the Bcl-2
family regulates apoptosis sensitivity.
An increase in the ratio of anti- to proapoptotic Bcl-2
proteins has been detected in various cancers and has been
correlated to tumor cell survival and apoptosis resistance.
More recently, Bcl-2 has also been implicated in the regu-
lation of the intracellular redox status [44]. Bcl-2 localizes
to mitochondrial membranes as well as the endoplasmatic
reticulum and the nuclear envelope, which are all sites
of ROS production [45]. While Bcl-2 has initially been
described as an anti-oxidant because of its inhibitory eﬀect
on H2O2-induced lipid peroxidation [46], there is also
evidence that Bcl-2 may promote a prooxidant intracellular
milieu. Accordingly, ectopic expression of Bcl-2 resulted
in an elevated constitutive level of superoxide anion and
intracellular pH in leukemia cells [47]. Conversely, reduction
of intracellular superoxide sensitized Bcl-2-overexpressing
tumor cells to apoptotic stimuli independent of the mito-
chondria [47]. These ﬁndings provide a link between
oncogene-mediated alterations in the intracellular redox
status and cell survival.4 International Journal of Cell Biology
3.2.2. Cytochrome c. Besides Bcl-2, also cytochrome c has
been implicated in the redox regulation of apoptosis. Once
cytochrome c is released from mitochondria into the cytosol,
it triggers formation of the cytochrome c/Apaf-1/Caspase-
9-containing apoptosome, which in turn lead to activation
of caspase-9 and downstream eﬀector caspases [48]. There
is recent evidence that also the redox state of cytochrome c
is involved in the regulation of apoptosis. To this end, the
oxidized form of cytochrome c (Fe(3+)) has been reported
to induce caspase activation via the apoptosome, while
the reduced form of cytochrome c (Fe(2+)) is unable to
do so [49–51]. Several mechanisms have been discussed
to be responsible for this redox-mediated regulation of
cytochromecactivity,includingdiﬀerentaﬃnitiesoftheoxi-
dized versus the reduced form of cytochrome c for binding
to Apaf-1, diﬀerent abilities of these cytochrome c forms
to activate Apaf-1, or, alternatively, diﬀerent aﬃnities for
other factors not belonging to the apoptosome. Regardless
of the exact mechanisms, this regulation of the redox state of
cytochrome c opens the possibility of controlling the eﬀector
phase of apoptosis at a postmitochondrial level.
Besides these genetic alterations in Bcl-2 family proteins,
impairment of mitochondrial apoptosis may also occur at
the postmitochondrial level. For example, expression level
or activity of Apaf-1 may be reduced due to promoter
hypermethylation or loss of heterozygosity at chromosome
12q22-23, which in turn leads to impaired assembly of a
functional apoptosome [52–56].
3.3. Evasion of Apoptosis via Aberrant Expression of “Inhibitor
of Apoptosis” (IAP) Proteins. Moreover, tumor resistance to
apoptosis may be caused by aberrant expression or function
of “Inhibitor of Apoptosis” (IAP) proteins. IAP proteins
are a family of endogenous caspase inhibitors with eight
human members, that is, XIAP, cIAP1, cIAP2, survivin,
livin (ML-IAP), NAIP, Bruce (apollon), and ILP-2 [10, 57].
All IAP proteins have at least one baculovirus IAP repeat
(BIR) domain that is required for classiﬁcation as IAP
family protein. This domain is also the region of the protein
that mediates the interaction with caspases [58]. Among
the IAP family proteins, XIAP exhibits the strongest anti-
apoptotic properties and inhibits apoptosis signaling by
bindingtoactivecaspase-3and-7andbypreventingcaspase-
9a c t i v a t i o n[ 59].
The expression and function of IAP proteins are tightly
regulated by several mechanisms, among them is transla-
tional regulation [60]. To this end, it is particularly inter-
esting to note that XIAP and cIAP1 belong to the proteins,
which are translated via an internal ribosome entry site
(IRES). This unique property enables protein translation of
theseIAPproteinsevenundercellularstressconditionswhen
protein synthesis is usually shut down, for example, because
of caspase-dependent breakdown of eukaryotic translation
initiation factors coupled with activation of the double-
stranded RNA-activated protein kinase PKR [61].
Typically, mRNA molecules are translated via a cap-
dependent translation mechanism [62]. However, the
mRNAs encoding XIAP or cIAP1 protein contain very long
5  untranslated regions (UTRs), which are not amenable
to a ribosome-scanning translation initiation mechanism
and thus, require a cap-independent translation initiation
mechanism, that is, IRES-mediated translation [60]. IRES-
mediated translation allows for the continued translation
of XIAP and cIAP1 even under conditions where cap-
dependent translation is inhibited such as cellular stress
[60]. In addition, IRES-mediated translational regulation
of XIAP and cIAP1 expression enables a rapid response
to transient cellular stress conditions in order to delay cell
death and ensure survival. Of note, cellular stress signals,
including low-dose irradiation, anoxia, serum starvation and
chemotherapeutic drugs, have been reported to stimulate the
IRES activity of XIAP or cIAP1 [63–66]. This is in line with
the concept that such stress signals promote cell survival
under stress conditions, at least in part, via IRES-mediated
upregulation of anti-apoptotic proteins.
4. Conclusions
Evasion of apoptosis is one of the hallmarks of human can-
cers that promote tumor formation and progression as well
as treatment resistance. Cellular stress signals can contribute
to evasion of apoptosis by activating anti-apoptotic and
cell survival programs that ultimately block cell death. This
interference with proper apoptosis signaling under stress
conditions can occur at diﬀerent points of the apoptosis
signaling network, for example, within the death receptor
or the mitochondrial pathway or at the postmitochondrial
level. Whether or not cellular stress eventually engages cell
survival or cell death programs also depends on the type
and strength of the stress stimulus as well as the cell type.
A better understanding of the molecular mechanisms of
this interplay between the cellular stress response and anti-
apoptotic programs is expected to yield novel molecular
targets for therapeutic interventions. The aim is to prevent
protective responses in order to maximize the antitumor
activity of anticancer treatment approaches. This strategy
will hopefully lead to more eﬀective treatment options for
cancer patients.
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